How does the economic value analysis often justify the initial higher cost of implementing smart packaging technology?
By preventing costly trial failures attributed to non-adherence issues
While the initial development and implementation costs for smart packaging may exceed those of traditional foil and plastic, the economic justification lies in the return on investment, particularly within clinical research. Late-stage clinical trials represent massive financial investments, and if results are later undermined because subjects failed to take medication correctly—a common occurrence—the resulting cost of that non-adherence is substantial. High-fidelity adherence data provided by smart packs can safeguard trial results, potentially accelerating regulatory approval or stopping the launch of a drug that would prove ineffective in the real world due to poor patient uptake. In this context, the added expense functions as an essential insurance policy against data integrity failures in crucial research stages.
